Skip to main content

Table 2 Patient characteristics by HCV genotype

From: Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

 

HCV genotype (no. of patients)

 

Characteristics

1a (n = 32)

1b (n = 30)

Gender

  

Male

22 (68.7%)

17 (56.6%)

Female

10 (31.2%)

13 (43.3%)

Demographics

  

Italian

31 (96.8%)

25 (83.3%)

Others

1 (3.1%)

5 (16.6%)

No. of HIV-1/HCV co- infected patients receiving HAART

8 (25%)

2 (6.6%)

Median HCV viral load (UI/ml) in HCV mono-infected patients

1,614,064 (range 6,743-7,985,320)

991,975 (range 3,470-4,381,000)

Median HCV viral load (UI/ml) in HCV/HIV co-infected patients

2,367,635 (range 46,801-7,985,320)

473,597 (range 46,801-900,393)

No. of patients naïve to peg IFN/RBV

26 (81.2%)

29 (96.6%)

  1. HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; HAART, Highly Active Anti-Retroviral Therapy; IFN, Interferon; RBV, Ribavirin.